This overview of the fifth edition of the WHO classification of thymic epithelial tumors
(including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]) …

Targeting checkpoints of immune cell activation has been demonstrated to be the most
effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Immune checkpoint inhibitors are a new class of anticancer therapies that amplify T-cell-
mediated immune responses against cancer cells. Immune checkpoint inhibitors have …

Cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4) or programmed death-1 (PD-
1)/programmed death-ligand 1 (PD-L1)–based immune checkpoint inhibitors (ICIs) have led …

PURPOSE Limited treatment options exist for patients with thymic epithelial tumor (TET)
whose disease progresses after platinum-based chemotherapy. We conducted a phase II …

Background Thymic carcinoma is a rare malignant disease and standard treatment for
advanced or metastatic thymic carcinoma previously treated with platinum-based …

Background: Inhibitors targeting programmed cell death 1 (PD-1) and programmed death-
ligand 1 (PD-L1) have unprecedented effects in cancer treatment. However, the objective …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …